Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Orexigenic Stories

2008-09-04 12:00:32

US-based pharmaceutical company Corcept Therapeutics has announced that Eli Lilly and Company has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzapine induced weight gain. Corcept has previously published the results of studies in rats that demonstrated that CORLUX, a potent GRII (cortisol) receptor antagonist, both reduced the weight gain associated with the ongoing use of olanzapine and mitigated the...